Breast Cancer, AstraZeneca
FDA Approves Metastatic Breast Cancer Drug, Datroway
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or metastatic hormone receptor HR+, HER2- breast cancer in adult patients who have previously received endocrine-based therapy and chemotherapy for unresectable or metastatic disease, according to a news release.
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Beloved TV host Ananda Lewis shares her story and a message to Black women about prioritizing their health in the new year.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
"Boy Meets World" star Danielle Fishel said she is finished with radiation treatment for cancer and opened up about the side ...
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
A cancer charity warned the experience of having cancer was also getting worse for many people, with delays to treatment and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback